Toronto Dominion Bank boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 4.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,820 shares of the biopharmaceutical company’s stock after buying an additional 1,207 shares during the quarter. Toronto Dominion Bank’s holdings in Alnylam Pharmaceuticals were worth $3,911,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. Eagle Health Investments LP grew its position in shares of Alnylam Pharmaceuticals by 13.8% during the 2nd quarter. Eagle Health Investments LP now owns 149,380 shares of the biopharmaceutical company’s stock valued at $21,787,000 after acquiring an additional 18,136 shares during the period. AIA Group Ltd bought a new position in Alnylam Pharmaceuticals during the second quarter valued at $421,000. Bank of Montreal Can increased its position in Alnylam Pharmaceuticals by 4.5% in the second quarter. Bank of Montreal Can now owns 77,081 shares of the biopharmaceutical company’s stock worth $11,218,000 after buying an additional 3,330 shares during the last quarter. Forsta AP Fonden raised its stake in shares of Alnylam Pharmaceuticals by 24.5% in the second quarter. Forsta AP Fonden now owns 29,000 shares of the biopharmaceutical company’s stock valued at $4,230,000 after buying an additional 5,700 shares during the period. Finally, Mackenzie Financial Corp lifted its position in shares of Alnylam Pharmaceuticals by 8.4% during the 2nd quarter. Mackenzie Financial Corp now owns 21,006 shares of the biopharmaceutical company’s stock valued at $3,064,000 after buying an additional 1,630 shares during the last quarter. Hedge funds and other institutional investors own 93.21% of the company’s stock.
Alnylam Pharmaceuticals Stock Performance
Shares of NASDAQ ALNY opened at $208.49 on Friday. The stock’s 50-day moving average is $203.32 and its 200 day moving average is $177.92. The stock has a market cap of $25.65 billion, a price-to-earnings ratio of -21.34 and a beta of 0.54. Alnylam Pharmaceuticals, Inc. has a 1-year low of $117.58 and a 1-year high of $236.80. The company has a current ratio of 3.48, a quick ratio of 3.33 and a debt-to-equity ratio of 3.85.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on ALNY shares. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, August 4th. Evercore ISI upped their price target on shares of Alnylam Pharmaceuticals to $252.00 in a research note on Tuesday, August 9th. Oppenheimer boosted their target price on shares of Alnylam Pharmaceuticals from $170.00 to $256.00 and gave the company an “outperform” rating in a report on Friday, September 9th. Jefferies Financial Group raised their price target on Alnylam Pharmaceuticals from $218.00 to $232.00 and gave the stock a “buy” rating in a report on Monday, October 3rd. Finally, Barclays decreased their price objective on Alnylam Pharmaceuticals from $240.00 to $236.00 and set an “overweight” rating on the stock in a research note on Friday, October 28th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $232.37.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.